Indivior PLC (LON:INDV – Get Free Report) shares reached a new 52-week high during mid-day trading on Thursday . The company traded as high as £1,453 ($1,794.71) and last traded at GBX 1,425 ($17.60), with a volume of 782614 shares. The stock had previously closed at GBX 1,514 ($18.70).
Indivior Price Performance
The business has a fifty day moving average price of GBX 1,618.62 and a 200-day moving average price of GBX 1,443.10. The company has a current ratio of 0.97, a quick ratio of 1.52 and a debt-to-equity ratio of 240.17. The stock has a market capitalization of £1.94 billion, a PE ratio of 146,400.00, a PEG ratio of -5.57 and a beta of -0.05.
Insider Transactions at Indivior
In other news, insider Mark Crossley sold 10,549 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of GBX 1,617 ($19.97), for a total value of £170,577.33 ($210,693.34). Company insiders own 3.21% of the company’s stock.
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Read More
- Five stocks we like better than Indivior
- ESG Stocks, What Investors Should Know
- A Mega Market Reset for Meta Platforms Stock
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Nucor Stock Earnings Riding the Steel Industry Wave
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Simpson Manufacturing: Buy This Future Dividend King While Down
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
